Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joy A Cavagnaro

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Human Gene Therapy|April 23, 2021
It's All About the DoseJoy A Cavagnaro
Nature Reviews. Drug Discovery|July 18, 2002
Preclinical safety evaluation of biotechnology-derived pharmaceuticalsJoy A Cavagnaro
Expert Opinion on Biological Therapy|October 2, 2003
'Generic' or 'follow-on' biologics: scientific considerations and safety issuesJames D Green, Lincoln Tsang, Joy A Cavagnaro
Human Gene Therapy. Clinical Development|May 23, 2013
Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studiesTimothy K MacLachlan, Maritza McIntyre, Kyriacos Mitrophanous, et al.
Regulatory Toxicology and Pharmacology : RTP|June 19, 2010
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticalsJay Tibbitts, Joy A Cavagnaro, Christine A Haller, et al.
Toxicologic Pathology|October 8, 2010
Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directionsMichael W Leach, Wendy G Halpern, Carol W Johnson, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Human Gene Therapy|April 23, 2021
It's All About the DoseJoy A Cavagnaro
Nature Reviews. Drug Discovery|July 18, 2002
Preclinical safety evaluation of biotechnology-derived pharmaceuticalsJoy A Cavagnaro
Expert Opinion on Biological Therapy|October 2, 2003
'Generic' or 'follow-on' biologics: scientific considerations and safety issuesJames D Green, Lincoln Tsang, Joy A Cavagnaro
Human Gene Therapy. Clinical Development|May 23, 2013
Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studiesTimothy K MacLachlan, Maritza McIntyre, Kyriacos Mitrophanous, et al.
Regulatory Toxicology and Pharmacology : RTP|June 19, 2010
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticalsJay Tibbitts, Joy A Cavagnaro, Christine A Haller, et al.
Toxicologic Pathology|October 8, 2010
Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directionsMichael W Leach, Wendy G Halpern, Carol W Johnson, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1